This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Effect of Intralesional 2-Interferon on Actinic Keratoses

Libby Edwards, MD; Norman Levine, MD; Melissa Weidner, RN; Michael Piepkorn, MD; Kenneth Smiles, PhD

Arch Dermatol. 1986;122(7):779-782.

Abstract
The effect of intralesional 2-interferon (IFN) on actinic keratoses was examined in this two-part study. In phase I, 11 of 12 lesions cleared following nine injections of IFN (5 x 10⁵ IU per dose) compared with none of 12 keratoses injected with placebo. Smaller doses of IFN (1 x 10⁵ IU and 1 x 10⁴ IU per injection) produced clearing of 42% and 58% of lesions, respectively. The second phase, which was designed to investigate the optimum schedule for treatment with IFN, showed that a minimum of six injections of IFN (5 x 10⁵ IU per injection) was necessary to clear 14 of 15 actinic keratoses. Although this mode of delivery is not practical for clinical use, intralesional 2-IFN demonstrates biologic activity against actinic keratoses.

(Arch Dermatol 1986;122:779-782)

Author Affiliations
From the Department of Internal Medicine, Section of Dermatology, University Medical Center, Tucson (Drs Edwards and Levine); the Department of Medicine, Division of Dermatology (Ms Weidner and Dr Piepkorn), and the Department of Pathology (Dr Piepkorn), University of Utah School of Medicine, Salt Lake City; and the Schering-Plough Corporation, Kenilworth, NJ (Dr Smiles).

Footnotes
Accepted for publication Jan 8, 1986.

Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dosing With 5% Imiquimod Cream 3 Times per Week for the Treatment of Actinic Keratosis: Results of Two Phase 3, Randomized, Double-blind, Parallel-Group, Vehicle-Controlled Trials
Korman et al.
Arch Dermatol 2005;141:467-473.
ABSTRACT | FULL TEXT  

Treatment of Cutaneous Squamous Cell Carcinomas by Intralesional Interferon Alfa-2b Therapy
Edwards et al.
Arch Dermatol 1992;128:1486-1489.
ABSTRACT  

Flushing Reactions in the Cancer Chemotherapy Patient: The Lists Are Longer but the Strategies Are the Same
Wilkin
Arch Dermatol 1992;128:1387-1389.
ABSTRACT  

The Effect of an Intralesional Sustained-Release Formulation of Interferon Alfa-2b on Basal Cell Carcinomas
Edwards et al.
Arch Dermatol 1990;126:1029-1032.
ABSTRACT  

Interferon: Promises, Disappointments, and Tempered Optimism
Edwards
Arch Dermatol 1987;123:743-744.
ABSTRACT